ARTICLE | Finance
Selective investment
How selectivity of c-MET inhibitor OMO-1 pushed VCs to back Octimet series A
January 21, 2017 12:55 AM UTC
Investors in Octimet Oncology N.V.’s series A round believe the selectivity of OMO-1 for its target, plus a clean safety profile, can differentiate the molecule from a sea of other programs in clinical development.
On Jan. 19, Octimet raised €11.3 million ($12 million) in a series A round led by V-Bio Ventures and Fund+. Droia Oncology Ventures and Omnes Capital also participated. Octimet is developing small molecule inhibitors of c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene) that the newco in-licensed from the Janssen Pharmaceutica N.V. unit of Johnson & Johnson (NYSE:JNJ), which received an undisclosed equity stake. ...